STAT3 and melanoma: Our combination of SGI-1776 and the PI3K inhibitor AZD6482 in 3D melanoma models showed that inhibition of AKT signaling is better achieved by the combination treatment; phosphorylated levels of STAT3 were also reduced, highlighting the benefits of inhibiting multiple pathways involved in melanoma resistance [8].